Spyre Therapeutics (SYRE) Common Equity (2015 - 2026)

Spyre Therapeutics has reported Common Equity for 12 years, with the latest figure at $670.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 39.0% year-over-year to $670.8 million; the trailing twelve-month figure through Mar 2026 stood at $670.8 million (up 39.0% YoY), and the FY2025 full-year result was $715.2 million, up 38.13% from the prior year.
• Common Equity for Q1 2026 stood at $670.8 million, down from $715.2 million in the prior quarter.
• The five-year high for Common Equity was $715.2 million in Q4 2025, with the low at -$245.4 million in Q3 2023.
• Historically, Common Equity has averaged $245.9 million across 5 years, with a median of $184.0 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity plunged 463.26% — and 2024, when it surged 352.48%.
• Spyre Therapeutics' Common Equity stood at $50.3 million in 2022, then soared by 265.8% to $184.0 million in 2023, then soared by 181.39% to $517.8 million in 2024, then jumped by 38.13% to $715.2 million in 2025, then fell by 6.21% to $670.8 million in 2026.
• The last three Common Equity figures came in at $670.8 million (Q1 2026), $715.2 million (Q4 2025), and $455.1 million (Q3 2025), per Business Quant data.